2.24 -0.25 (-10.04%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 2.85 | 1-year : | 3.42 |
Resists | First : | 2.44 | Second : | 2.92 |
Pivot price | 2.19 | |||
Supports | First : | 1.66 | Second : | 1.38 |
MAs | MA(5) : | 2.46 | MA(20) : | 2.16 |
MA(100) : | 1.97 | MA(250) : | 2.16 | |
MACD | MACD : | 0.1 | Signal : | 0.1 |
%K %D | K(14,3) : | 61.8 | D(3) : | 74.2 |
RSI | RSI(14): 52.8 | |||
52-week | High : | 4.07 | Low : | 1.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INDP ] has closed below upper band by 45.5%. Bollinger Bands are 123.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 2.42 - 2.44 | 2.44 - 2.45 |
Low: | 2 - 2.02 | 2.02 - 2.03 |
Close: | 2.22 - 2.24 | 2.24 - 2.26 |
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Thu, 28 Mar 2024
Should You Buy Indaptus Therapeutics Inc (INDP) Stock After it Has Gained 0.44% in a Week? - InvestorsObserver
Wed, 27 Mar 2024
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth? - Yahoo Finance
Wed, 27 Mar 2024
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth? - Simply Wall St
Mon, 18 Mar 2024
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024 - BioSpace
Thu, 14 Mar 2024
Indaptus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary - TradingView
Wed, 06 Mar 2024
Should You Buy Indaptus Therapeutics Inc (INDP) Stock After it Has Fallen 5.56% in a Week? - InvestorsObserver
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 9 (M) |
Shares Float | 6 (M) |
Held by Insiders | 30.8 (%) |
Held by Institutions | 7 (%) |
Shares Short | 34 (K) |
Shares Short P.Month | 15 (K) |
EPS | -1.84 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.44 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -47.7 % |
Return on Equity (ttm) | -84.1 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.92 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -13 (M) |
Levered Free Cash Flow | -8 (M) |
PE Ratio | -1.23 |
PEG Ratio | 0 |
Price to Book value | 1.55 |
Price to Sales | 0 |
Price to Cash Flow | -1.43 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |